Jubilant Pharmova Ltd

Jubilant Pharmo Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Pharmova Ltd

₹ 974 0.30%
05 Jun - close price
jubl.com BSE: 530019 NSE: JUBLPHARMA
About

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Key Points

Business Segments & Revenue Contribution 9MFY24[1][2]
a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]

Website BSE NSE
  • Market Cap ₹ 15,509 Cr.
  • Current Price ₹ 974
  • High / Low ₹ 1,250 / 784
  • Stock P/E 35.5
  • Book Value ₹ 445
  • Dividend Yield 0.51 %
  • ROCE 8.99 %
  • ROE 6.55 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 43.9%
  • Company's working capital requirements have reduced from 28.6 days to 13.4 days

Cons

  • The company has delivered a poor sales growth of 6.31% over past five years.
  • Company has a low return on equity of 5.80% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -3.01%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,678 1,587 1,680 1,677 1,759 1,732 1,752 1,822 1,929 1,901 1,966 2,122 2,290
1,459 1,419 1,438 1,459 1,487 1,480 1,463 1,535 1,584 1,611 1,625 1,833 1,951
Operating Profit 219 168 242 218 271 252 289 287 345 290 341 289 339
OPM % 13% 11% 14% 13% 15% 15% 17% 16% 18% 15% 17% 14% 15%
21 9 19 49 -151 410 8 -10 9 12 4 -19 10
Interest 56 62 66 71 73 71 61 56 53 49 50 56 56
Depreciation 271 90 97 95 101 91 91 91 95 98 105 121 117
Profit before tax -86 25 98 101 -54 500 144 130 206 154 190 93 176
Tax % 16% 76% 37% 34% 15% 4% 29% 23% 27% 34% 37% 40% 32%
-100 6 62 66 -62 482 102 101 151 102 120 56 119
EPS in Rs -6.15 0.40 3.92 4.19 -3.68 30.26 6.45 6.33 9.64 6.46 7.55 3.51 7.50
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
5,751 5,749 5,861 7,518 9,111 5,976 6,099 6,130 6,282 6,703 7,234 8,280
5,141 4,493 4,510 5,995 7,367 4,428 4,695 4,980 5,503 5,802 6,061 7,020
Operating Profit 610 1,256 1,352 1,522 1,744 1,548 1,403 1,150 779 901 1,173 1,260
OPM % 11% 22% 23% 20% 19% 26% 23% 19% 12% 13% 16% 15%
86 4 19 36 -249 225 263 8 -9 -76 416 7
Interest 368 371 341 284 220 200 184 145 188 272 240 212
Depreciation 288 347 291 415 371 340 349 382 554 382 369 440
Profit before tax 40 542 738 859 904 1,233 1,133 630 28 170 981 614
Tax % 200% 29% 22% 26% 36% 27% 26% 34% 333% 57% 15% 35%
-40 387 575 634 577 898 836 413 -65 73 836 398
EPS in Rs -3.63 24.60 36.14 40.35 36.06 56.39 52.47 25.98 -3.83 4.84 52.69 25.02
Dividend Payout % -83% 12% 8% 7% 12% 9% 10% 19% -130% 102% 9% 20%
Compounded Sales Growth
10 Years: 4%
5 Years: 6%
3 Years: 10%
TTM: 14%
Compounded Profit Growth
10 Years: 1%
5 Years: -13%
3 Years: 47%
TTM: -22%
Stock Price CAGR
10 Years: 12%
5 Years: 5%
3 Years: 39%
1 Year: -15%
Return on Equity
10 Years: 10%
5 Years: 4%
3 Years: 6%
Last Year: 7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 16 16 16 16 16 16 16 16 16 16 16 16
Reserves 2,438 2,951 3,420 4,071 4,793 5,588 4,726 5,303 5,383 5,418 6,239 7,077
4,793 4,493 4,045 3,469 4,840 4,808 2,830 3,192 3,677 3,664 2,731 3,615
1,372 1,280 1,417 1,902 1,670 1,898 1,192 1,319 1,853 2,240 3,598 4,815
Total Liabilities 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,830 10,929 11,338 12,584 15,523
4,911 5,104 5,107 5,401 5,648 6,340 4,609 4,871 5,183 5,091 5,176 8,044
CWIP 597 611 684 671 901 768 897 1,090 1,562 2,103 3,630 2,962
Investments 40 85 103 124 115 69 241 239 256 42 44 61
3,071 2,939 3,006 3,262 4,654 5,133 3,017 3,631 3,928 4,101 3,735 4,455
Total Assets 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,830 10,929 11,338 12,584 15,523

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
783 1,099 1,268 1,303 1,122 1,543 1,784 838 661 971 1,072 1,227
-362 -309 -465 -614 -1,018 -267 -727 -323 -474 -596 512 -1,260
-503 -843 -686 -901 657 -1,050 -1,709 -33 -157 -432 -1,453 95
Net Cash Flow -82 -52 117 -212 761 225 -652 482 30 -58 132 62
Free Cash Flow 434 760 806 819 473 975 1,270 241 -135 83 -38 -120
CFO/OP 141% 91% 104% 103% 84% 116% 155% 90% 111% 131% 112% 114%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 52 60 63 55 51 79 49 55 56 50 45 47
Inventory Days 169 207 223 177 147 463 268 308 268 220 178 170
Days Payable 99 106 137 145 106 273 124 139 160 146 158 170
Cash Conversion Cycle 122 162 149 87 92 268 194 224 165 124 65 47
Working Capital Days 12 4 50 45 45 62 74 56 57 56 16 13
ROCE % 6% 13% 15% 15% 16% 15% 12% 10% 3% 7% 10% 9%

Insights

In beta
Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Global Presence (Countries Served)
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Radiopharmacies (USA)
Number
CDMO Sterile Injectable Capacity Expansion Project Cost (Spokane)
USD Million
Cumulative US ANDA Approvals
Number
Global Vitamin B3 Market Ranking
Rank
Drug Discovery FTE Capacity
Number
Number of Integrated Drug Discovery Programs Delivered
Number
Radiopharmaceuticals Manufacturing Capacity Utilization
%
Ruby-Fill (Cardiac PET) US Market Share
%
US Radiopharmacy Volume Market Share
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 47.67% 47.67% 47.67% 47.67%
23.20% 23.20% 20.29% 19.06% 19.50% 17.94% 16.96% 17.23% 17.40% 16.56% 15.96% 15.90%
1.63% 1.64% 2.89% 3.77% 4.06% 5.66% 6.99% 7.05% 9.52% 10.53% 11.23% 11.63%
23.91% 23.89% 25.56% 25.91% 25.18% 25.17% 24.82% 24.48% 24.83% 24.60% 24.57% 24.25%
0.59% 0.59% 0.58% 0.58% 0.58% 0.56% 0.56% 0.56% 0.56% 0.63% 0.57% 0.56%
No. of Shareholders 93,37589,37686,58892,26481,99289,4561,02,44296,52699,67393,33690,13386,347

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls